Cargando…

EUFOREA consensus on biologics for CRSwNP with or without asthma

Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fokkens, Wytske J., Lund, Valerie, Bachert, Claus, Mullol, Joaquim, Bjermer, Leif, Bousquet, Jean, Canonica, Giorgio W., Deneyer, Lauren, Desrosiers, Martin, Diamant, Zuzana, Han, Joseph, Heffler, Enrico, Hopkins, Claire, Jankowski, Roger, Joos, Guy, Knill, Andrew, Lee, Jivianne, Lee, Stella E., Mariën, Gert, Pugin, Benoit, Senior, Brent, Seys, Sven F., Hellings, Peter W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972984/ https://www.ncbi.nlm.nih.gov/pubmed/31090937 http://dx.doi.org/10.1111/all.13875

Ejemplares similares

Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds
por: Chuang, Chien‐Chia, et al.
Publicado: (2021)

A EUFOREA comment on a lost comorbidity of asthma
por: Conti, Diego M., et al.
Publicado: (2023)

Comparison of different medical treatment options for CRSwNP: doxycycline, methylprednisolone, mepolizumab and omalizumab
por: De Schryver, Els, et al.
Publicado: (2015)

Rapid and Continuing Improvements in Nasal Symptoms with Dupilumab in Patients with Severe CRSwNP
por: Bachert, Claus, et al.
Publicado: (2022)

Allergic respiratory disease care in the COVID-19 era: A EUFOREA statement
por: Scadding, Glenis K., et al.
Publicado: (2020)

The argument against the use of dupilumab in patients with limited polyp burden in chronic rhinosinusitis with nasal polyposis (CRSwNP)
por: Hardison, Scott A., et al.
Publicado: (2023)

White Paper on European Patient Needs and Suggestions on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA
por: De Prins, Louise, et al.
Publicado: (2022)

Clinical characteristics of patients with CRSwNP with intensely high eosinophil level
por: Ma, Ling, et al.
Publicado: (2022)

Adverse events for biologics in patients with CRSwNP: A meta‐analysis
por: Shen, Yang, et al.
Publicado: (2022)

Profiling Disease and Economic Burden in CRSwNP Using Machine Learning
por: Bhattacharyya, Neil, et al.
Publicado: (2022)

Nasal cytology and histology in CRSwNP: Two sides of the same coin
por: Gelardi, Matteo, et al.
Publicado: (2023)

Corrigendum on: White paper on European patient needs and suggestions on chronic type 2 inflammation of airways and skin by EUFOREA
por: De Prins, Louise, et al.
Publicado: (2022)

Real‐life assessment of chronic rhinosinusitis patients using mobile technology: The mySinusitisCoach project by EUFOREA
por: Seys, Sven F., et al.
Publicado: (2020)

EUFOREA summit in Brussels 2023: inspiring the future of allergy & respiratory care
por: Hellings, P. W., et al.
Publicado: (2023)

Differences in men and women suffering from CRSwNP and AERD in quality of life
por: Bartosik, Tina J., et al.
Publicado: (2020)

Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil
por: Anselmo-Lima, Wilma T., et al.
Publicado: (2021)

Olfaction Recovery following Dupilumab Is Independent of Nasal Polyp Reduction in CRSwNP
por: Cantone, Elena, et al.
Publicado: (2022)

Measuring Nasal Patency and the Sense of Smell in CRSwNP Patients Treated with Dupilumab
por: Ottaviano, Giancarlo, et al.
Publicado: (2023)

Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab
por: Ledda, Andrea Giovanni, et al.
Publicado: (2023)

A new allergic rhinitis therapy (MP29-02*) provides effective and rapid symptom relief for patients who suffer most from the bothersome symptoms of nasal congestion or ocular itch
por: Fokkens, Wytske, et al.
Publicado: (2015)

Real‐life effectiveness of biological therapies on symptoms in severe asthma with comorbid CRSwNP
por: Mümmler, Carlo, et al.
Publicado: (2021)

Necroptosis Underlies Neutrophilic Inflammation Associated with the Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
por: Xie, Yadong, et al.
Publicado: (2021)

Effectiveness of Dupilumab in the Treatment of Adult and Older Adult Patients with Severe, Uncontrolled CRSwNP
por: Ottaviano, Giancarlo, et al.
Publicado: (2023)

Eosinophil-mast cell pattern of intraepithelial infiltration as a marker of severity in CRSwNP
por: Gelardi, Matteo, et al.
Publicado: (2023)

Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium: a BelSACI-Abeforcal-EUFOREA statement
por: Hellings, P. W., et al.
Publicado: (2019)

WITHDRAWN: Dupilumab: A review of potential in the treatment of Chronic rhinosinusitis with nasal polyps (CRSwNP)
por: Sree Sudha, T.Y., et al.
Publicado: (2020)

Epithelial immune regulation of inflammatory airway diseases: Chronic rhinosinusitis with nasal polyps (CRSwNP)
por: Klimek, Ludger, et al.
Publicado: (2022)

Real-life effectiveness of dupilumab in patients with mild to moderate bronchial asthma comorbid with CRSwNP
por: Minagawa, Shunsuke, et al.
Publicado: (2022)

Cost–Utility Analysis of Dupilumab for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Italy
por: De Corso, Eugenio, et al.
Publicado: (2022)

Calprotectin in nasal secretion: a new biomarker of non-type 2 inflammation in CRSwNP
por: De Corso, Eugenio, et al.
Publicado: (2022)

The “real life” efficacy of dupilumab is independent of initial polyp size and concomitant steroids in CRSwNP
por: Campion, Nicholas J., et al.
Publicado: (2023)

A new intranasal therapy (MP29-02*) is more effective than current firstline therapy regardless of season, symptom or severity.
por: Bachert, Claus, et al.
Publicado: (2015)

Identification of gaps in the current allergic rhinitis guidelines and how these can be filled
por: Bousquet, Jean, et al.
Publicado: (2015)

Efficacy of Biologics on Refractory Eosinophilic Otitis Media Associated with Bronchial Asthma or Severe Uncontrolled CRSwNP
por: De Corso, Eugenio, et al.
Publicado: (2022)

How to manage recurrences after surgery in CRSwNP patients in the biologic era: a narrative review
por: De Corso, Eugenio, et al.
Publicado: (2023)

Real-world evidence for the effectiveness and safety of dupilumab in patients with CRSwNP after 1 year of therapy
por: Albrecht, Tobias, et al.
Publicado: (2023)

Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab
por: Piazzetta, Giovanna Lucia, et al.
Publicado: (2023)

Checklist for the Multidisciplinary Approach to United Airway in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and asthma
por: Castillo Vizuete, José Antonio, et al.
Publicado: (2022)

Endotype-driven treatment in chronic upper airway diseases
por: De Greve, Glynnis, et al.
Publicado: (2017)

A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress
por: Hellings, Peter W., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_v2ishhr8lf9arhuf8uff9obic3